Bladder cancer drug trial halted early after enrolling just 4 patients
NCT ID NCT05581589
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small study tested whether giving the drug sacituzumab govitecan before surgery could help people with a rare type of muscle-invasive bladder cancer. The drug targets cancer cells and delivers chemotherapy directly to them. Only 4 people took part before the study was stopped early, so we don't have enough information to know if it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw could detect bladder Cancer's return — a trial puts it to the test
- New strategy aims to eliminate residual bladder cancer after drug combo
- Keytruda may let some bladder cancer patients avoid bladder removal
- Scientists hunt for clues in bladder Cancer's surrounding tissue
- Experimental triple therapy for advanced cancers shows early promise but trial halted
- New Drug-Radiation combo aims to spare bladders in cancer patients